| abstract |
The present invention relates to antisense LNA oligonucleotides (oligomers) complementary to CARD9 pre-mRNA intron and exon sequences, which are capable of inhibiting the expression of CARD9 protein. Inhibition of CARD9 expression is beneficial for a range of medical disorders including inflammatory bowel disease, pancreatitis, IgA nephropathy, primary sclerosing cholangitis, cardiovascular disease, cancer and diabetes. |